Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of biomarkers in the preparation of drugs for predicting the feedback response of 5-aminosalicylic acid in the treatment of ulcerative colitis

A technology of ulcerative colitis and biomarkers, applied in the field of biomedicine, can solve the problems of no feedback response, unclear pathophysiology and other factors, and achieve the effect of disease control

Active Publication Date: 2015-12-23
HAYAO CIHANG PHARM CO LTD +1
View PDF4 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But to date, no relevant biomarkers and systems are available to determine the feedback response when treating UC patients with 5-ASA
[0006] As shown above, one of the mainstays of conventional treatment for UC is the use of 5-ASA, but the efficacy of 5-ASA in the treatment of active UC is only 30-40%
UC pathophysiology and other factors affecting response to 5-ASA therapy are not well understood

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of biomarkers in the preparation of drugs for predicting the feedback response of 5-aminosalicylic acid in the treatment of ulcerative colitis
  • Application of biomarkers in the preparation of drugs for predicting the feedback response of 5-aminosalicylic acid in the treatment of ulcerative colitis
  • Application of biomarkers in the preparation of drugs for predicting the feedback response of 5-aminosalicylic acid in the treatment of ulcerative colitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0057] The present invention provides gender-dependent serum target biomarkers that can be used to predict the use of 5-ASA to treat different colonic sites (left semicolitis, proctosigmoid, pancolitis, and extensive colitis) in patients with mild to moderate UC.

[0058] Application of 5-ASA unresponsive serum biomarkers in personalized clinical practice

[0059] As noted above, 60% of patients with moderate UC encountered clinical failures when treated with 5-ASA compared with 80% when treated with placebo. Due to a lack of understanding of the pathophysiology of the disease, 5-ASA therapy does not take into account differences in sex and lesion site in the colon. Personalized drug therapy based on the development of clinical biomarkers will provide more effective, individualized treatment options. Different panels of protein target biomarkers have been identified in the present invention and used to distinguish differences in response to 5-ASA treatment due to differences...

Embodiment 2

[0070]For predicting 5-ASA response in female patients with left-sided colitis. A patient with confirmed left-sided colitis was identified first, and left-sided colitis was confirmed by routine colonoscopy. Usually, 5-ASA is prescribed to patients as a routine drug in the treatment of left colitis. Before treating a patient's colitis, the clinician performs one or more blood tests and obtains the samples, then prepares the serum, and finally uses the appropriate 5-ASA non-responsive target biomarkers mentioned above to determine its relative s level. The measured target biomarker levels were compared with the standard values ​​shown in Table 2, and the results obtained were the predictions of the efficacy of 5-ASA (doses were 2.4 g 5-ASA / day and 4.8 g 5-ASA / day , efficacy of a 6-week course of treatment in female patients with left-sided colitis). For example, if the patient's specific 5-ASA does not show significant differences in the levels of target biomarkers in respons...

Embodiment 3

[0077] Methods and systems for predicting 5-ASA response in male patients with left-sided colitis. A patient with confirmed left-sided colitis was identified first, and left-sided colitis was confirmed by routine colonoscopy. Usually, 5-ASA is prescribed to patients as a routine drug in the treatment of left colitis. Before treating a patient's colitis, the clinician performs one or more blood tests and obtains the samples, then prepares the serum, and finally uses the appropriate 5-ASA non-responsive target biomarkers mentioned above to determine its relative s level. The measured target biomarker levels were compared with the standard values ​​shown in Table 3, and the results obtained were the predictions of the efficacy of 5-ASA (doses were 2.4 g 5-ASA / day and 4.8 g 5-ASA / day , efficacy of a 6-week course of treatment in a male patient with left-sided colitis). For example, if the patient's specific 5-ASA does not show significant differences in the levels of target bio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of a biomarker for preparing a medicine for predicting feedback response of 5-aminosalicylic acid in treatment of ulcerative colitis. The biomarker determined in the invention is the basis of a target biomarker associated with gender difference response when 5-aminosalicylic acid (5-ASA) is used to treat ulcerative colitis (UC). The biomarker comprises a group of protein biomarkers which can differentiate response difference for treatment by 5-ASA between different genders and determine the curative effect by using 5-ASA under different UC conditions. Meanwhile, a novel drug target for a UC novel curative method is effectively determined and verified by using the biomarker with specificity for genders and disease focus parts, novel diagnostic reagents, medicines, methods and diagnostic standards are developed, and the application is used for establishing a UC treatment policy.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to the application of biomarkers in the preparation and prediction of feedback response medicines for treating ulcerative colitis with 5-aminosalicylic acid. Background technique [0002] Ulcerative colitis (UC, referred to as ulcer) is a recurrent inflammatory bowel disease (IBD) that occurs in the large intestine or colon. Patients with UC often exhibit the same symptoms as patients with irritable bowel syndrome (IBS), although the symptoms are milder in patients with IBS, which also complicates the diagnosis of UC. Likewise, it is also possible that the patient's indeterminate colitis is not ulcerative colitis, but more similar to another inflammatory bowel disease, Crouse's colitis. [0003] From an anatomical point of view, the symptoms of each UC patient are different, and the lesion can be located only in the sigmoid colon or extend to the entire colon. Init...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): G01N33/96
Inventor 段燕文王锋布鲁斯·亚克欣
Owner HAYAO CIHANG PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com